In a pivotal development this year, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) in August 2024 for emergency use in type 1 allergic reactions, such as anaphylaxis.
Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the ...